- Implement strategies to evaluate anhedonia in patients with MDD
- Evaluate clinical trial data for glutamatergic therapies for treatment-resistant depression
- Integrate novel glutamatergic therapies into individualized management plans for patients who are not responding to standard anti-depressant therapy
- Analyze clinical trial data for long-acting injectable agents for schizophrenia
- Integrate counseling strategies for long-acting injectable medications into individualized management plans for patients with schizophrenia
- Implement strategies to identify patients with TD
- Differentiate between the characteristics of different therapies for TD
- Design individualized management plans for patients with TD
- Describe the criteria used to define difficult-to-treat depression.
- Assess the safety and efficacy of VNS in the management of difficult-to-treat depression.
- Implement strategies to identify patients with difficult-to-treat depression who may be appropriate candidates for VNS therapy.
Jersey City Psychiatry 2026: Spotlight CE Sessions
Scroll down to view information on each symposium. These symposia are hybrid. In-Person registration is included as part of Jersey City Psychiatry 2026 registration.
Cases and Conversations: Integrating Glutamatergic Agents to Advance Care for Patients with MDD
October 2, 2026 10:45 AM - 11:45 AM ET
OVERVIEW
Affecting more than 17.3 million Americans, major depressive disorder (MDD) is 1 of the most common mental disorders in the United States (US). MDD can negatively impact quality of life (QoL) and lead to increased functional disability, morbidity, and mortality. A major gap in the quality of care of patients with MDD exists, as evidenced by the significant percentage of patients who do not achieve remission, even after multiple treatment attempts. The purpose of this continuing education program is to enhance awareness of and update clinicians on novel therapeutic targets that may provide options for effective treatment options for patients with MDD so that clinicians can more effectively manage their patients with MDD early to optimize patient outcomes and improve QoL.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
TARGET AUDIENCE
This educational activity is directed toward psychiatrists, psychiatric NPs, PAs, RNs, pharmacists and other HCPs involved in the management of patients with MDD.
ACCREDITATION/CREDIT DESIGNATION
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
ACKNOWLEDGEMENT OF EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Axsome Therapeutics, Inc.
AGENDA
10:45 AM ET | Welcome and Introductions
10:55 AM ET | Evaluating Anhedonia
11:10 AM ET | The Growing Role of Glutamatergic Therapies in the Management of Patients with MDD
11:40 AM ET | Closing Remarks
11:45 AM ET | Adjourn
Integrating Motivational Interviewing Techniques to Overcome Barriers to the use of Long-Acting Injectable Agents in Patients with Schizophrenia
October 2, 2026 12:15 PM - 1:15 PM ET
OVERVIEW
Schizophrenia is a significant mental illness that is characterized by features of psychosis, apathy, social withdrawal, and cognitive impairment that often lead to functional impairment and poor health-related quality of life. Many patients have debilitating residual symptoms, difficulties with adherence, and drug-related adverse effects. Non-adherence to medication is associated with a higher risk of relapse and hospitalization, and this can affect up to 74% of patients by 18 months of treatment. Long-acting injectable (LAI) antipsychotic medications have been developed to try to address these concerns through the elimination of daily dosing, reducing fluctuations in serum concentration, and allowing for regular monitoring. However, the use of LAIs remains limited among clinicians due to a lack of awareness and negative perceptions.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
TARGET AUDIENCE
This educational activity is directed toward psychiatrists, psychiatric NPs, PAs, RNs, pharmacists and other HCPs involved in the management of patients with Schizophrenia.
ACCREDITATION/CREDIT DESIGNATION
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
ACKNOWLEDGEMENT OF EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Johnson & Johnson Innovative Medicine.
AGENDA
12:15 PM ET | Welcome and Introductions
12:25 PM ET | Optimizing Adherence for Patients with Schizophrenia
12:40 PM ET | How to Integrate Motivational Interviewing into Practice for Patients with Schizophrenia
1:05 PM ET | Closing Remarks
1:15 PM ET | Adjourn
Cases and Conversations: Improving Identification and Management of Patients with Tardive Dyskinesia
October 2, 2026 2:25 PM - 3:25 PM ET
OVERVIEW
The primary cause of tardive dyskinesia (TD) is the long-term use of dopamine receptor-blocking agents (DRBAs), including many agents used to treat schizophrenia, major depressive disorder (MDD), and bipolar disorder. It is characterized by slow, or tardive, onset of involuntary movements, which primarily affect the face, lips, tongue, trunk, and extremities. These involuntary movements can affect patients' daily function and quality of life (QoL). Traditionally, no FDA-approved agents were available to treat TD, so using medications with lower risk of TD and tapering medications at the first sign of TD symptoms was considered the best approach. The 2017 FDA approval of vesicular monoamine transporter-2 (VMAT2) inhibitors shifted the TD treatment paradigm, and the updated 2020 American Psychiatric Association (APA) guidelines now recommend that patients with moderate-to-severe or disabling TD be treated with a reversible VMAT2 inhibitor.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
TARGET AUDIENCE
This educational activity is directed toward psychiatrists, psychiatric NPs, pharmacists, PAs, RNs, and other HCPs involved in the management of patients with TD.
ACCREDITATION/CREDIT DESIGNATION
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
ACKNOWLEDGEMENT OF EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Neurocrine Biosciences, Inc.
AGENDA
2:25 PM ET | Welcome and Introductions
2:35 PM ET | Diagnosing Tardive Dyskinesia
2:50 PM ET | Integrating the Latest Data into Individualized Management Plans for Tardive Dyskinesia
3:15 PM ET | Closing Remarks
3:25 PM ET | Adjourn
Optimizing Treatment for Difficult-to-Treat Depression: The Role of Vagal Nerve Stimulation Therapy
October 2, 2026 3:55 PM - 4:55 PM ET
OVERVIEW
Major depressive disorder (MDD) is a prevalent and often disabling psychiatric illness that affects millions of individuals in the United States (US). Despite a broad array of antidepressant therapies (ADTs), response remains suboptimal. Up to two-thirds of patients do not achieve remission with initial treatment, and relapses are common, even among those who initially respond. Difficult-to-treat depression (DTD), previously referred to as treatment-resistant depression, can affect the psychological and well as physical quality of life for patients. Vagal nerve stimulation (VNS) is a neuromodulatory therapy approved for chronic or recurrent depression that has not responded to multiple treatments; however, VNS is increasingly being considered earlier in the treatment course for patients with DTD, especially those with recurrent illness, functional impairment, and poor response to medication and psychotherapy.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
TARGET AUDIENCE
This educational activity is directed toward psychiatrists, psychiatric NPs, PAs, RNs, and other HCPs involved in the management of patients with difficult-to-treat depression.
ACCREDITATION/CREDIT DESIGNATION
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
ACKNOWLEDGEMENT OF EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from LivaNova.
259 Prospect Plains Rd, Building H, Monroe, NJ 08831
Copyright ©2026
Physicians' Education Resource®, LLC.
All rights reserved
.png)